median (25th – 75th 98 (95 – 100) 97 (94 – 99) (0·9) percentile) 0 – 20%, as % of group 0 0 0 21 – 50%, as % of group 0 0 0 51 – 80%, as % of group 0 0 0 80 – 100%, as % of 100 100 0 group Duration of ESRD (years) median (25th – 75th 11·1 (3·1 -18·1) 10·9 (3·8 -18·5) -0·2 (0·9) percentile) No of prev tx (% of patients) 0 34·2 36 -1·8 1 46·7 43·3 3·4 2 15·8 18·1 -2·3 3 3·3 0·7 Female (% of patients) 62·5 60·4 Blood Group (% of patients) O 48·7 46·9 1·8 A 32·9 34·0 -1·1 AB 13·8 14·1 -0·3 B 4·6 4·9 -0·3 Diabetes as primary 0·7 0·7 0 cause of ESRD (% of patients) Length of time registered in paired scheme 0 (not registered) 62·5 84·0 -21·5 0 – 12 months 15·8 7·4 8·4 >12 months 21·7 8·6 13·1 Appendix Table 2: Mean differences of matching run using 10 to 1 matches to index cases Characteristic ‘HLAi’ Matched Controls Difference in means n = 213 n = 2130 (Ratio of variances) Age (years) 44 ± 11 48 ± 12 -3·1 (1·) (mean ± SD) cRF median (25th – 75th 96 (79 99) 87 (57 -96) 7·9 (0 9)
median (25th – 75th percentile) 0 – 20%, as % of group 21 – 50%, as % of group 51 – 80%, as % of group 80 – 100%, as % of group 98 (95 – 100) 0 0 0 100 97 (94 – 99) 0 0 0 100 (0·9) 0 0 0 0 Duration of ESRD (years) median (25th – 75th percentile) 11·1 (3·1 -18·1) 10·9 (3·8 -18·5) -0·2 (0·9) No of prev tx (% of patients) 0 1 2 3 34·2 46·7 15·8 3·3 36 43·3 18·1 -1·8 3·4 -2·3 0·7 Female (% of patients) 62·5 60·4 Blood Group (% of patients) O A AB B 48·7 32·9 13·8 4·6 46·9 34·0 14·1 4·9 1·8 -1·1 -0·3 -0·3 Diabetes as primary cause of ESRD (% of patients) 0·7 0·7 0 Length of time registered in paired scheme 0 (not registered) 0 – 12 months >12 months 62·5 15·8 21·7 84·0 7·4 8·6 -21·5 8·4 13·1 Appendix Table 2: Mean differences of matching run using 10 to 1 matches to index cases Characteristic ‘HLAi’ n = 213 Matched Controls n = 2130 Difference in means (Ratio of variances) Age (years) (mean ± SD) 44 ± 11 48 ± 12 -3·1 (1·) cRF median (25th – 75th 96 (79 99) 87 (57 -96) 7·9 (0 9)